IN8bio (INAB)
(Real Time Quote from BATS)
$0.32 USD
0.00 (-0.34%)
Updated Sep 20, 2024 03:10 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
IN8bio, Inc. [INAB]
Reports for Purchase
Showing records 1 - 17 ( 17 total )
Company: IN8bio, Inc.
Industry: Medical - Biomedical and Genetics
Continued Success of INB-100 Paves the Way for Potential Registrational Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IN8bio, Inc.
Industry: Medical - Biomedical and Genetics
Cell Therapy Deep Dive: Turning the Tide From Oncology to Autoimmune
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: IN8bio, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging INB-200 Data Bodes Well for INB-400; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IN8bio, Inc.
Industry: Medical - Biomedical and Genetics
Expect Major Clinical Data Updates at Mid-Year; Adjusting PT to $12.50; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IN8bio, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Data Strengthens Proof-of-Concept For INB-300; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IN8bio, Inc.
Industry: Medical - Biomedical and Genetics
Expect Multiple Pipeline Updates Throughout 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IN8bio, Inc.
Industry: Medical - Biomedical and Genetics
Positive Data From INB-100 Allow for Continued Evaluation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IN8bio, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Clinical Data Readouts by Year-End; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IN8bio, Inc.
Industry: Medical - Biomedical and Genetics
Updates on INB-100 and INB-200 Remain Near-Term Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IN8bio, Inc.
Industry: Medical - Biomedical and Genetics
INB-400 to Enter Phase 2 by Year-End; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IN8bio, Inc.
Industry: Medical - Biomedical and Genetics
Updates From INB-200 are the Next Major Milestones; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IN8bio, Inc.
Industry: Medical - Biomedical and Genetics
Positive Efficacy Update Validates INB-100; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IN8bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: IN8bio, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways From Our Fireside Chat with Dr. Michael Bishop on AML
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IN8bio, Inc.
Industry: Medical - Biomedical and Genetics
INB-200 and INB-100 Continue to Show Promise; Catalyst-Rich 2023 Expected; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IN8bio, Inc.
Industry: Medical - Biomedical and Genetics
INB-100 Data Update Expected at ASH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: IN8bio, Inc.
Industry: Medical - Biomedical and Genetics
Harnessing Gamma-Delta T Cells Into Oncotherapy; Initiate With Buy and a $14 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
|